Esperion Therapeutics (ESPR) Tops Q3 EPS by 6c

Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($0.37), $0.06 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $34 million versus the consensus estimate of $29.59 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c